Treatment of equine degenerative joint disease with autologous peripheral blood-derived mesenchymal stem cells: a case report

A 5-year-old German Warmblood stallion with chronic lameness, attributable to degenerative joint disease (DJD) of the pastern joint unresponsive to medical treatments, was treated with autologous mesenchymal stem cells (MSC). These MSC were isolated from the peripheral blood (PB) of the patient and injected into the pastern joint, at a concentration of 2.5x10^6 cells, twice with an 8-week interval. The positive response to this stem cell treatment was documented by visual gait evaluation as well as objective pressure plate analyses. This paper is the first to describe the use of autologous PB-derived MSC to treat a horse suffering from chronic DJD. The favorable outcome of this single case may stimulate further research on the use of equine peripheral blood as a source of autologous MSC in equine regenerative medicine.

INTRODUCTION

Degenerative joint disease is a major cause of diminished athletic function and wastage in performance horses (Frisbie 2005; Jeffcott et al. 1982; McIlwraith 1982). Ideally, all treatment should be based upon a good knowledge of the anatomy and physiology of the normal joints and the processes occurring during degeneration and repair (Goodrich and Nixon 2006; McIlwraith and Vachon 1988; Nizolek and White 1981). Initially, such treatment should include some degree of rest or exercise restriction. Medical treatments for DJD may include anti-inflammatory and analgesic drugs to reduce inflammation and pain, and so-called disease modifying drugs, such as glucosamine or chondroitin sulphate or hyaluronic acid (Goodrich and Nixon 2006; Malone 2002; Nizolek and White 1981). In the presence of severe cartilage and bone changes, the use of articular cartilage curettage, osteophyte removal and even arthrodesis could be suitable in some cases (Malone 2002; Zubrod and Schneider 2005). Nevertheless, the aforementioned therapies are merely palliative or may aim at an enhanced repair, albeit without actual regeneration of the affected joint. Over the last decades, the field of equine regenerative medicine has been getting increased attention and the use of stem cells to treat joint pathologies appears to be a promising strategy to regenerate injured tissues by differentiation towards cells with a hyaline-like cartilage morphology and which are able to produce cartilage-specific components, such as collagen type II and glycosaminoglycans (Berg et al. 2009; Koch and Betts 2007).

Stem cells are defined as cells displaying a self-renewal capacity either with or without differentiation, depending on the symmetry of the division (Donovan and Gearhart 2001). More specifically, MSC are adult stem cells derived from the mesodermal germ layer. Current clinical regenerative therapies with MSC in horses mainly use bone marrow (BM)-derived MSC for the treatment of tendinopathies (Crovace et al. 2007; Smith 2006, 2008; Smith et al. 2003; Violini et al. 2009) and BM- or adipose tissue (AT)-derived MSC for the treatment of osteoarthritis (Frisbie et al. 2009).
In general, obtaining BM and AT samples is invasive and they are quite difficult to harvest. As an alternative, scientists have suggested umbilical cord blood (UCB), which, in humans, can be easily collected at birth. However, in horses, autologous UCB is not always available and a sterile collection is only possible under highly hygienic circumstances, which is difficult to achieve under field circumstances. The disadvantages of UCB can be avoided by using peripheral blood (PB) as a source for MSC. Since the collection of a sterile blood sample can easily be performed by any equine practitioner, PB is a readily accessible source of autologous MSC when injuries occur.

This paper is the first to describe the use of autologous PB-derived MSC to treat a horse suffering from chronic lameness attributable to DJD.

CASE HISTORY

One year before the injection of autologous PB-derived MSC, a 5-year-old German Warmblood stallion was presented with severe unilateral forelimb lameness, attributable to DJD of the pastern joint. The diagnosis was made based on clinical and radiographic examination and a positive response to intra-articular anesthesia. Dorsopalmar and lateromedial radiographs revealed periarticular new bone formation (Figure 1). Initial medical treatment with oral non-steroidal anti-inflammatory drugs and box rest during two months, and subsequently the intra-articular administration of steroidal anti-inflammatory medication and hyaluronic acid did not improve the impaired locomotion. Two months later, an additional period of one month of complete box rest and limited movement in a small paddock for the following five months did not show any improvement of the lameness. Given the lack of response to therapy after almost one year, the owners opted for treatment with autologous PB-derived MSC. The ethical committee of the Faculty of Veterinary Medicine, Ghent University, Belgium (EC2010-147) approved the experimental design.

TREATMENT

Ten mL of blood was taken from the vena jugularis of the patient and centrifuged at 1000 xg for 20 minutes at room temperature (RT). The buffy coat fraction was collected and diluted 1:1 with phosphate buffered saline (PBS). Subsequently, the cell suspension was gently layered on a Percoll gradient (density 1.080 g/mL; GE Healthcare) and centrifuged at 600 xg for 15 minutes at RT. The MSC were maintained and characterized by the presence or absence of different immunophenotypic markers and by in vitro differentiation towards osteoblasts, chondroblasts and adipocytes as previously described (De Schauwer et al. 2011).

For the first intra-articular injection, 2.5x10⁶ autologous PB-derived MSC of passage 1 (P₁) were resuspended in 2.5 mL of sterile PBS with 50 µg/mL gentamicin (Sigma-Aldrich, Bornem, Antwerp, Belgium) and injected into the pastern joint of the patient. A similar injection was repeated eight weeks later with cryopreserved MSC of P₁, which were further cultured up to P₃. The intra-articular injections were performed after the clipping and aseptic preparation of the skin, as is routinely done before an intra-articular treatment is started.

Figure 2 gives an overview of the timing of the injections with the autologous PB-derived MSC and all evaluations of the patient, as described below.

OUTCOME

Clinical assessment

Clinical evaluation was performed four weeks before injection (T₁), and at 4-week-intervals after the first injection (T₂= 4 weeks, T₃= 8 weeks, T₄= 12 weeks and T₅= 16 weeks), according to the scoring system of the American Association of Equine Practitioners (AAEP) by the same team of veterinarians: grade 0 corresponds to soundness and grade 5 to non-weight-bearing lameness. At every time point, flexion tests of the affected lower limb were performed and the results were graded from 0 (no response) to 3 (severe lameness).

Four weeks before the first injection (T₁), the la-
Lameness was evaluated and localized in the pastern joint using intra-articular anesthesia. A score of 4/5 was given, which implied that the horse showed severe lameness at the walk and the trot in a straight line, with a marked head nod and shortened stride. Moreover, the flexion test of the distal limb was strongly positive (3/3). Two days after the first injection with the autologous MSC, a mild diffuse swelling was observed at the pastern. This swelling disappeared within a day. After three days of box rest, gradual hand-walking was initiated. Four weeks after the first injection (T1), the lameness was obviously decreased, although it could still be observed consistently at the trot under all circumstances tested. Therefore, a score of 3/5 was given. The flexion test at that time point was only slightly positive (1/3). After the second MSC injection, a mild, localized swelling together with a mild, transient lameness was observed at the walk. At all subsequent evaluation time points (T2, T3 and T4), only a residual irregularity at the trot could be noticed when lunging the horse (grade 2/5) and the flexion tests were negative (0/3).

**Pressure plate analysis**

Recently, pressure plate analysis has been proposed as a useful tool to quantify equine locomotion and to evaluate the effects of a therapy in horses (Oosterlinck et al. 2010a; Oosterlinck et al. 2010b). Indeed, this technique allows simultaneous analyses of different limbs and provides detailed information on the loading of the different portions of the foot during a complete stance period. In this case, the horse was walked and trotted over a pressure plate (RSscan 3D 2m-system, RSscan International, Olen, Belgium) in a custom-made walkway, as described previously (Oosterlinck et al. 2010a; Oosterlinck et al. 2010b). A trial was considered valid only if a complete hoof print of at least one forelimb was recorded while the velocity was within a preset range. Each measuring session was limited to the number of trials necessary to obtain five valid measurements of both forelimbs. The following kinetic variables were calculated for both forelimbs at the walk and at the trot, and expressed as % symmetry (left/right x 100%): (1) peak vertical force (PVF), i.e. the maximal vertical force value throughout the stance phase; (2) vertical impulse (VI), calculated by time integration of the force-time curves and (3) load rate (LR) of the vertical force curve.

The peak vertical force (PVF), vertical impulse (VI) and load rate (LR) symmetry ratios at all time points are presented in Figure 3. Already after the first injection with the autologous PB-derived MSC, an increase of the LR symmetry ratio was observed in both the walk and the trot, which even further increased considerably after the second injection (Figure 3). Clear improvements were also seen in the PVF and VI symmetry ratios, although these effects were more pronounced at the trot than at the walk (Figure 3).

**Medical imaging**

Routine dorsopalmar and lateromedial radiographic evaluation of the pastern joint did not reveal considerable changes after the autologous MSC therapy compared to pre-treatment radiographs (data not shown). Four weeks before stem cell therapy, an ultrasonographic examination was performed and did not show any abnormalities. Therefore, no further ultrasonography was performed.

**DISCUSSION**

Mesenchymal stem cells represent a very promising therapeutic tool for certain types of degenerative or traumatic diseases in different animal species, because...
of their enormous plasticity and differentiation capacities. The in vivo use of MSC in equine veterinary medicine has been studied intensively, with several independent studies reporting regenerative effects, mainly in tendon and ligament injuries (Crovace et al. 2007; Smith 2008). Equine degenerative joint disease is one of the most common causes of early retirement and reformation of sport horses, and therefore, the use of MSC is currently being explored for its regenerative potential in this musculoskeletal injury (Berg et al. 2009; Koch and Betts 2007). To the knowledge of the authors, there are only reports on the in vivo use of equine adipose tissue (AT)-derived and bone marrow (BM)-derived MSC for the treatment of osteoarthritis (Frisbie et al. 2009; Wilke et al. 2007). In these studies, osteoarthritis was experimentally induced and the MSC were injected in the acute phase of the lesion (within 14 days). A short-term clinical improvement was noticed after MSC therapy, although this was not the case for the long-term follow-up of the horses. In contrast, a more recent study by McIlwraith showed no evidence of any clinically significant improvement in the joints injected with BM-MSC, but arthroscopic evaluation confirmed a significant increase in aggrecan production, repair tissue firmness and a trend for better overall repair tissue quality in BM-MSC-treated joints. (McIlwraith et al. 2011). This latter study emphasizes the importance of combining clinical evaluation with more scientifically-based parameters to evaluate the efficacy of MSC treatment in horses.

In the present case report, the authors describe for the first time the use of peripheral blood (PB)-derived MSC to treat a horse suffering from chronic lameness attributable to DJD of the pastern joint. A positive response to the therapy could already be demonstrated four weeks after the first injection, as assessed by the clinical evaluations and pressure plate analyses. For the latter, it was proven that the load rate (LR) symmetry ratio increased considerably in both gaits, indicating an increased speed of loading at the walk as well as at the trot. Moreover, a clear improvement in peak vertical force (PVF) and vertical impulse (VI) symmetry ratios was evident at the trot, indicating an increased symmetry of the weight-bearing function of the forelimbs. The lack of an overall increasing improvement in PVF and VI symmetry ratios at the walk is most likely associated with a lower reproducibility of the pressure plate analysis at the walk than at the trot, as previously reported (Oosterlinck et al. 2010a). Currently, i.e. one year after the MSC treatment, the stallion is not showing any signs of recurrent lameness and he is competing again (personal communication with the horse owner). Still, in order to truly confirm the effectiveness of PB-MSC, a double blinded standardized model should have been used with exactly the same induced lesions in a large number of horses, including control groups. Moreover, and in analogy to previously performed experiments in horses where the fate of injected BM-MSC was studied in an equine tendon injury model (Guest et al. 2010), fluorescently-labelled PB-MSC could be used to prove whether the in vivo cartilage regeneration is attributable to the MSC itself or rather to the products they secrete.

In conclusion, this case report is the first to describe the successful treatment of a patient suffering from chronic lameness attributable to DJD using autologous PB-derived MSC. It is clear that this single case study does not allow to draw definite conclusions on the clinical efficacy of the treatment protocol, nor does it allow for an extrapolation to other equine pathologies beyond DJD. However, the results of this case report are encouraging to further evaluate the efficacy of autologous PB-derived MSC in equine regenerative medicine.

ACKNOWLEDGEMENTS

This study was supported by a grant to the first author from the agency for Innovation by Science and Technology (IWT).
REFERENCES


WEGENS UITBREIDING VAN ONS MULTIDISCIPLINAIRE TEAM, ZIJN WIJ OP ZOEK NAAR EEN:

MEDEWERKER TECHNISCHE ONDERSTEUNING (DIERENARTS M/V) O.B.V. EEN FULLTIME DIENSTVERBAND

FUNCTIE
Technische ondersteuning van ons volledige productengamma, waaronder wij verstaan:
• Het vertalen van technische en wetenschappelijke informatie naar praktijkgerichte en/of commerciële teksten ten behoeve van onze verkoop- en marketingmedewerkers in binnen en buitenland
• Informatievoorziening aan klanten en distributeurs, almede het oplossen van praktische vraagstukken
• Het houden van presentaties voor collega’s, dierenartsen en veehouders
• Het volgen van de ontwikkelingen in de veehouderij op Europees niveau en interne communicatie en informatievoorziening hieromtrent

PROFIEL
• Dierenarts met enkele jaren praktijkervaring in de varkenshouderij
• Goede beheersing van MS Office (Word, Power Point en Excel)
• Uitstekende beheersing van Nederlandse en Engelse taal in woord en geschrift
• Een enthousiaste teamplayer met goede sociale en communicatieve vaardigheden
• Creativiteit en analytisch denkvermogen om verworven inzichten te vertalen naar de dagelijkse praktijk

WIJ BIEDEN
• Een uitdagende en veelzijdige functie
• Een inspirerende werkomgeving
• Goede primaire en secundaire arbeidsvoorzieningen

INFORMATIE
Voor meer informatie over de functie kunt u contact opnemen met Ellis Draaijer, Technical support manager van Dopharma Research B.V., telefoonnummer +31 (0)162 58 2000. Voor uitgebreide informatie over onze organisatie verwijzen wij u naar onze website www.dopharma.com.

Mocht u belangstelling hebben voor deze vacature en herkent u zich in bovengenoemd profiel, dan zien wij uw sollicitatie t.a.v. Vivian Couwenberg, afdeling Personeelszaken (e-mail: pz@dopharma.com), graag binnen 4 weken na publicatiedatum tegemoet op onderstaand adres:

DOPHARMA VETERINAIRE FARMACA B.V.
POSTBUS 205
4940 AE RAAMSDONKSVEER
NEDERLAND
TEL. +31 (0)162 582000
E-MAIL: PR@DOPHARMA.COM

DOPHARMA VETERINAIRE FARMACA
PROGRESS MAKES THE DIFFERENCE